Dr. Emens on the Future of Immunotherapy in Ovarian Cancer

Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.

Leisha A. Emens, MD, PhD, professor of medicine, Hematology/Oncology, co-leader, Hillman Cancer Immunology and Immunotherapy Program, director, Translational Immunotherapy for the Women’s Cancer Research Center, UPMC Hillman Cancer Center, discusses a potential future with immunotherapy in ovarian cancer.

It is understood that moving immunotherapy to the frontline setting elicits greater efficacy for women with ovarian cancer, explains Emens. Additionally, PD-L1—positive patients derive a greater benefit from the agents currently available in this space.

As such, the future of immunotherapy in ovarian cancer requires a good signal of activity with available agents. Clinical trials that incorporate biomarker analyses may allow investigators to better predict which patients are more likely to respond to this modality of treatment, concludes Emens.

Related Videos
David Samuel Dicapua Siegel, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
 Philip McCarthy, MD
Lova L. Sun, MD, MSCE
Robert M. Rifkin, MD, FACP
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
Andrew Ip, MD
Anthony B. El-Khoueiry, MD